NCT03626636

A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

Completed Phase 2 Last updated 8 July 2020

What this trial tests

Phase 2 trial testing Risuteganib in Dry Age-related Macular Degeneration in 42 participants. Completed in 4 April 2019.

Timeline

1 August 2017

Primary endpoint
4 April 2019

4 April 2019

Quick facts

Lead sponsor	Allegro Ophthalmics, LLC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	42
Start date	1 August 2017
Primary completion	4 April 2019
Estimated completion	4 April 2019
Sites	7 locations across United States

Drugs / interventions tested

• Risuteganib — full drug profile →
• Sham

Conditions studied

• Dry Age-related Macular Degeneration — all drugs for Dry Age-related Macular Degeneration →

Sponsor

Allegro Ophthalmics, LLC — full company profile →

Who can join

Adults 50 to 85, any sex, with Dry Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and exploratory efficacy of 1.0mg of Luminate® in patients with Intermediate Non-Exudative Macular Degeneration

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting integrin pathways: mechanisms and advances in therapy.
   Pang X, He X, Qiu Z, Zhang H, et al · · 2023 · cited 704× · PMID 36588107 · DOI 10.1038/s41392-022-01259-6
2. Emerging therapeutic opportunities for integrin inhibitors.
   Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, et al · · 2022 · cited 394× · PMID 34535788 · DOI 10.1038/s41573-021-00284-4
3. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions.
   Cabral de Guimaraes TA, Daich Varela M, Georgiou M, Michaelides M. · · 2022 · cited 135× · PMID 33741584 · DOI 10.1136/bjophthalmol-2020-318452
4. Age-Related Macular Degeneration Revisited: From Pathology and Cellular Stress to Potential Therapies.
   Hadziahmetovic M, Malek G. · · 2020 · cited 69× · PMID 33569380 · DOI 10.3389/fcell.2020.612812
5. Recent Advances in Age-Related Macular Degeneration Therapies.
   Fabre M, Mateo L, Lamaa D, Baillif S, et al · · 2022 · cited 68× · PMID 36014339 · DOI 10.3390/molecules27165089
6. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules.
   Nebbioso M, Lambiase A, Cerini A, Limoli PG, et al · · 2019 · cited 39× · PMID 30987401 · DOI 10.3390/ijms20071693
7. An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma.
   Ghanchi F, Bourne R, Downes SM, Gale R, et al · · 2022 · cited 35× · PMID 34974541 · DOI 10.1038/s41433-021-01766-w
8. The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.
   Borchert GA, Shamsnajafabadi H, Hu ML, De Silva SR, et al · · 2023 · cited 28× · PMID 37626902 · DOI 10.3390/cells12162092